Mark Johnson, MD
Gastroenterology · Chula Vista, CANPI 1861421372
Payments from drug & device makers
Across 31 payments — averaging $45.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$278
- Novo Nordisk$239
- Boston Scientific$194
- Cook Medical LLC$179
- Mallinckrodt Hospital Products Inc.$119
- Johnson & Johnson$117
- plus $288 from 10 others
What the payments were for
- Food & beverage$1,24388%
- Education$1007%
- Gifts$725%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 5 | $278 |
| Novo Nordisk | 2 | $239 |
| Boston Scientific | 3 | $194 |
| Cook Medical LLC | 5 | $179 |
| Mallinckrodt Hospital Products Inc. | 1 | $119 |
| Johnson & Johnson | 3 | $117 |
| Braintree Laboratories, Inc. | 1 | $72 |
| Intercept Pharmaceuticals, Inc. | 2 | $60 |
| Exelixis Inc. | 1 | $39 |
| AMAG Pharmaceuticals, Inc. | 2 | $24 |
| ERBE USA Inc | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $16 |
| AbbVie | 1 | $16 |
| Romark Laboratories, LC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$228
- Wegovy$120
- Saxenda$119
- TERLIVAZ$119
- GENERAL - BILIARY DEVICES$112
How this compares
$1,414 in reported general payments places this provider in the 40th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 59 | $1,400 |
| Dicyclomine Hcl | 26 | $690 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 12 | $311 |
| Fluoxetine Hcl | 14 | $232 |
| Pantoprazole Sodium | 14 | $216 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Chula Vista
- Gregory WienerChula Vista$3.5M
- Erick AlayoChula Vista$1000K
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.